Restoring mucosal barrier function

Synedgen's first-in-class therapeutics improve patient outcomes by promoting barrier function to repair mucosal injury

Protecting the gastrointestinal (GI) tract from injury

Synedgen’s current lead asset is MIIST305, a clinic-ready, orally delivered therapeutic that repairs GI mucosal injury. MIIST305 restores GI function and reduces unchecked inflammation and damage.

First-In-Class Therapies to Protect, Restore, and Repair the Body

Targeted therapies

Scalable GMP production

Excellent safety profiles

Strong IP Position